Head-to-head evidence
AZD9550 vs mazdutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/glucagon receptor (dual) · full Obesity pipeline
AZD9550
Developed by AstraZeneca
NCT06862791 · Phase 2 · completed
The study uses randomization, quadruple blinding, multiple placebo-controlled treatment groups, and includes 377 participants. Its primary endpoints are clinical weight-loss measures, but the results and whether the primary comparisons were met are not yet available, so the evidence cannot be rated as strong.
Next expected readout: October 2026 · NCT07017179 (registry estimate)
mazdutide
Developed by Eli Lilly and partners
NCT05607680 · Phase 3 · completed
The trial was randomized, blinded, and placebo-controlled with over 600 participants, and its primary endpoint was percent body-weight change, a disease-defining measure for obesity. Both mazdutide doses produced significantly greater weight loss than placebo (P<0.0001).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2026 · NCT06884293 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD9550's landscape · mazdutide's landscape